A deal has been signed between Aptamer Group and Flip Gene Therapeutics to support the development of inducible gene therapies. To control the expressions of gene therapy, the optimer binder will be developed as a gene switch.
Aptamer Group, a leading provider of custom optimer selection and development services, offers next-gen aptamers in the form of optimer binders to deliver high affinity, high stability, high specificity, and cost-effective production to provide innovations across life science. Flip Gene Therapeutics is a US-based biotechnology company intended to develop next-gen regulated gene therapeutics that are inducible and controllable.
Aptamer Group and Flip Gene Therapeutics have recently negotiated a deal to use Aptamer Group’s optimer technology to support Flip Gene Therapeutics’ gene therapy platform. In this agreement, it has been mentioned that Aptamer Group will develop optimer binders to several small-molecule targets, which will be incorporated into Flip Gene Therapeutics’ gene therapy platform. Its prime focus is to develop pharmacologically inducible gene therapeutics that are controllable using a gene switch.
Aptamer’s optimer binders support novel gene therapy development
Gene therapies are a therapeutics way to treat diseases and conditions by administering genetic material. Using the optimer binders as a gene switch’s component will help generate responsive gene expression that could easily be controlled by dosing certain small molecule drugs. However, optimer binders are oligonucleotide-based affinity ligands that offer a solution to support novel gene therapy development through their potential.
The platform comprises three parallel target-types specific discovery processes for proteins and peptides, small molecules, and cell targets. They are effective in providing solutions for novel gene therapy development.
According to Dr Arron Tolley, chief executive officer of Aptamer group, “This agreement will allow us for inducible treatments in the exciting field of gene therapy. We look forward to working with our partners to develop and assess the optimer binders to function as part of their gene therapy. This will, in turn, offer a strong endorsement of the technology.”
The agreement includes initial upfront payments for optimer development and further licensing payments for developing optimer binders and development and commercial milestone payments for clinical and commercial success.
